MS Views and News – a Patient Advocacy Organization that provides educational information for ALL affected by Multiple Sclerosis

Being Empowered with MS information IS beneficial.

Visit our archived education program video recordings. Visit

Visit our website: MS Views and

joomla ecommerce template

Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information



Saturday, January 5, 2013

A new drug for the treatment of Secondary Progressive Multiple Sclerosis (SPMS) called MIS416, developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, has been granted a patent in the United States

Auckland, New Zealand December 18 2012: A new drug for the treatment of secondary progressive multiple sclerosis (SPMS) called MIS416, developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, has been granted a patent in the United States.

Innates chief executive Simon Wilkinson says the US patent is a significant milestone as the US market represents around 70% of the worldwide MS market by revenue. He says currently there are no drugs approved to effectively treat SPMS.

The granting of the patent comes ahead of the worlds largest annual gathering of the healthcare/pharmaceutical investment sector in early January. The JP Morgan conference in San Francisco attracts major investors and pharmaceutical companies. While big listed companies take centre stage with their plans for the coming 12 months at the conference, Mr Wilkinson says companies like Innate will also be there talking with potential investors.

Following the success of our Phase 2A trials, where the data showed 80% of the patients had at least a 30% (or greater) improvement in at least one measure of MS related clinical status, we have attracted interest from both pharmas and investors, he says.

Innate is now looking to convert this interest into funding for a larger randomized Phase 2B clinical trial. Meanwhile patent applications for MIS416 have been filed in other major markets including Europe, United Kingdom and Australia.

In parallel with the planning for the 2B study, Innate has expanded its NZ 'compassionate use' access programme to allow 12 patients from the completed 2A trial to stay on treatment at the patients request. This brings the total number of patients with progressive MS who have received MIS416 on compassionate grounds to 21.

In 15 patients with SPMS who have received six or more doses, 13 (87%) have reported modest to significant improvement in their health-related quality of life.

Of the seven patients who have been on treatment for 20 weeks or more, six (86%) report sustained improvements. MS related quality of life improvements are measured using the internationally accepted "MS Quality of Life Inventory" (MSQLI) assessment tool.

Source: Click here 


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit:  to register


Lauren Singer said...

I live in South Africa. I first got ms when I was 16 and am now 49. Been in sp for past 15 or so years. My life has been stolen. Will this drug be available in South Africa? If so, when? What does it purport to ACTUALLY help?

Miss Chili said...

This MIS416 may not be a cure, but it sounds promising nonetheless. As for finding a cure, here's hoping that we're moving closer to it.

Stuart said...

Lauren - I would suggest that you contact the company (Innate) directly that it making this drug. Maybe you can enter their trial? It is truly not ready for marketing and by reading the article you wil find it is in beginning stages of research study. Let's all hope that this will eventually become a positive. - Regards, SS